|Phase of Study:||Phase II|
|Treatment Location:||Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions|
|Estimated Length of Stay in Houston:||None anticipated; however, will admit to hematology beds if the patient is |
admitted for adverse reactions or suspected side effects from this agent.
|Supported By:||Celator Pharmaceuticals, Inc.|
|Return Visit:||At least once weekly during first month, then at least at the start of each |
|Home Care:|| None|